keyword
MENU ▼
Read by QxMD icon Read
search

Migraine treatment emergency

keyword
https://www.readbyqxmd.com/read/30112726/efficacy-and-safety-of-dfn-11-sumatriptan-injection-3-mg-in-adults-with-episodic-migraine-a-multicenter-randomized-double-blind-placebo-controlled-study
#1
Stephen Landy, Sagar Munjal, Elimor Brand-Schieber, Alan M Rapoport
BACKGROUND: In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose. The primary objective of the study was to assess the efficacy and safety of acute treatment with DFN-11 compared with placebo in episodic migraine. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study of DFN-11 in the acute treatment of adults with episodic migraine (study RESTOR)...
August 15, 2018: Journal of Headache and Pain
https://www.readbyqxmd.com/read/30112725/efficacy-and-safety-of-dfn-11-sumatriptan-injection-3-mg-in-adults-with-episodic-migraine-an-8-week-open-label-extension-study
#2
Stephen Landy, Sagar Munjal, Elimor Brand-Schieber, Alan M Rapoport
BACKGROUND: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate the efficacy, tolerability, and safety of DFN-11 in the acute treatment of multiple migraine attacks. METHODS: This was an 8-week open-label extension of multicenter, randomized, double-blind, placebo-controlled US study. Subjects averaging 2 to 6 episodic migraine attacks per month were randomized to DFN-11 or placebo to treat a single attack of moderate-to-severe intensity and then entered the extension study to assess the efficacy, tolerability, and safety of DFN-11 in multiple attacks of any pain intensity...
August 15, 2018: Journal of Headache and Pain
https://www.readbyqxmd.com/read/30107027/multimorbidity-in-patients-with-chronic-migraine-and-medication-overuse-headache
#3
Domenico D'Amico, Emanuela Sansone, Licia Grazzi, Ambra M Giovannetti, Matilde Leonardi, Silvia Schiavolin, Alberto Raggi
OBJECTIVES: Patients with chronic migraine (CM) display a considerable amount of comorbidities, particularly psychiatric and cardiovascular, and the presence of multiple comorbidities, i.e. the so-called multimorbidity, is a risk factor for migraine chronification or maintenance of CM. Our aim is to address the rate and impact of multimorbidity in patients with CM and medication overuse headache (MOH). MATERIALS & METHODS: In a sample of patients with CM attending a structured withdrawal for coexisting MOH, we defined multimorbidity as the presence of two or more conditions in addition to CM-MOH...
August 14, 2018: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/30079481/effects-of-systemic-inhibitors-of-acid-sensing-ion-channels-1-asic1-against-acute-and-chronic-mechanical-allodynia-in-a-rodent-model-of-migraine
#4
Clément Verkest, Emilie Piquet, Sylvie Diochot, Mélodie Dauvois, Michel Lanteri-Minet, Eric Lingueglia, Anne Baron
BACKGROUND AND PURPOSE: Acid-Sensing Ion Channels (ASICs) are neuronal proton sensors emerging as potential therapeutic targets in pain of the orofacial region. Amiloride, a non-specific ASIC blocker, has been shown to exert beneficial effects in animal models of migraine and in patients. We explored the involvement of the ASIC1-subtype in cutaneous allodynia, a hallmark of migraine affecting cephalic and extra-cephalic regions in about 70% of migrainers. EXPERIMENTAL APPROACH: We investigated the effects on cephalic and extra-cephalic mechanical sensitivity of systemic injections of amiloride and mambalgin-1, a specific inhibitor of ASIC1a- and ASIC1b-containing channels, in a rodent model of acute and chronic migraine induced by intraperitoneal injections of isosorbide dinitrate...
August 5, 2018: British Journal of Pharmacology
https://www.readbyqxmd.com/read/30074551/headache-in-pregnancy
#5
Matthew S Robbins
PURPOSE OF REVIEW: Headache disorders are extraordinarily common and disproportionately impact women of childbearing age. This article reviews the importance of proper diagnosis, natural history, and management of headache disorders in pregnant and postpartum women. RECENT FINDINGS: Red flags for secondary headache specifically among pregnant women include elevated blood pressure and lack of a previous headache history, as well as a prolonged duration of the headache attack in those with a prior history of migraine...
August 2018: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/30073584/refining-the-benefit-risk-profile-of-anti-epileptic-drugs-in-headache-disorders
#6
REVIEW
Michael J Marmura, Aliza S Kumpinsky
Anti-epileptic drugs are among the most effective drugs for migraine prophylaxis, and will likely continue to have a role even as new therapies emerge. Topiramate and valproate are effective for the preventive treatment of migraine, and other medications such as gabapentin or lamotrigine may have a role in the treatment of those with allodynia or frequent aura, respectively. Oxcarbazepine, carbamazepine, phenytoin, gabapentin, and others may alleviate pain in trigeminal neuralgia. While many anti-epileptic drugs can be effective in those with migraine or other headaches, most of these agents can potentially cause serious side effects...
August 2, 2018: CNS Drugs
https://www.readbyqxmd.com/read/30059368/emergency-department-use-of-intravenous-prochlorperazine-for-acute-migraine
#7
Calli Cook, Brittany Newberry
The Research to Practice Column is designed to improve translational research critique skills of nurse practitioners (NPs). In this issue, the article "Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine" is discussed in the context of a patient with an acute headache presenting to the emergency department (ED). The study was designed to assess the efficacy of intravenous prochlorperazine and diphenhydramine as compared with intravenous hydromorphone for patients with acute migraine in the ED...
July 2018: Advanced Emergency Nursing Journal
https://www.readbyqxmd.com/read/30044691/cycling-through-migraine-preventive-treatments-implications-for-all-cause-total-direct-costs-and-disease-specific-costs
#8
Janet H Ford, Krista Schroeder, Allen W Nyhuis, Shonda A Foster, Sheena K Aurora
BACKGROUND: Migraine is a common and disabling neurological disease associated with substantial economic burden. Among patients with migraine, it is unknown if cost differences exist when preventive migraine medication (PMM) switches occur. OBJECTIVE: To understand the cost burden and health care resource utilization of patients who discontinue or cycle through 1 (PMM1), 2 (PMM2), or ≥ 3 (PMM3) unique PMM drug classes over a 12-month period versus patients who adhere persistently to their initial PMM class...
July 25, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/30014208/emerging-treatments-in-episodic-migraine
#9
REVIEW
Kate W Grimsrud, Rashmi B Halker Singh
PURPOSE OF REVIEW: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine. RECENT FINDINGS: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies...
July 16, 2018: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/29926909/predictors-of-first-line-treatment-success-in-children-and-adolescents-visiting-an-infusion-center-for-acute-migraine
#10
Serena L Orr, Marielle A Kabbouche, Paul S Horn, Hope L O'Brien, Joanne Kacperski, Susan LeCates, Shannon White, Jessica Weberding, Mimi N Miller, Scott W Powers, Andrew D Hershey
OBJECTIVES: To characterize a population of pediatric patients visiting an infusion center for acute migraine and determine predictors of first-line treatment success in this population. BACKGROUND: Though migraine is common in the pediatric emergency department and specialized infusion centers, little is known about this patient population and whether or not clinical data can be used to predict treatment response. METHODS: This was an observational study involving a retrospective analysis of data from visits to the Cincinnati Children's Hospital infusion center for treatment of an acute migraine...
June 21, 2018: Headache
https://www.readbyqxmd.com/read/29882776/the-role-of-magnesium-in-neurological-disorders
#11
REVIEW
Anna E Kirkland, Gabrielle L Sarlo, Kathleen F Holton
Magnesium is well known for its diverse actions within the human body. From a neurological standpoint, magnesium plays an essential role in nerve transmission and neuromuscular conduction. It also functions in a protective role against excessive excitation that can lead to neuronal cell death (excitotoxicity), and has been implicated in multiple neurological disorders. Due to these important functions within the nervous system, magnesium is a mineral of intense interest for the potential prevention and treatment of neurological disorders...
June 6, 2018: Nutrients
https://www.readbyqxmd.com/read/29881904/migraine-with-extensive-skin-markings-a-case-report
#12
Sabrina Berdouk, Sobia Khan
BACKGROUND: Migraines are a commonly seen complaint in the emergency department, but migraines with extensive skin markings have rarely been reported and so the cause is still unknown. CASE PRESENTATION: We report a 28-year-old Pakistani male complaining of recurrent migraines that are now associated with skin markings that appear on his forehead and last for a few days and then disappear on their own. A diagnosis of migraines with cutaneous markings was made. An MRI was done on the patient and showed normal results...
June 7, 2018: International Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29881652/migraine-treatment-in-the-emergency-department-alternatives-to-opioids-and-their-effectiveness-in-relieving-migraines-and-reducing-treatment-times
#13
REVIEW
Haley Dodson, Jay Bhula, Sven Eriksson, Khoa Nguyen
The objective of this literature review is to evaluate the efficacy of opioids for the treatment of headaches, particularly migraines, in the emergency department (ED). Despite safer alternatives, opiates are routinely used as an abortive treatment for migraine headaches. The studies reviewed demonstrate that opiates are less effective in terminating acute headaches and result in prolonged ED visits. Dopamine receptor antagonists, such as metoclopramide and prochlorperazine, were the most efficacious in terminating migraines in the studies examined...
April 6, 2018: Curēus
https://www.readbyqxmd.com/read/29878341/dfn-02-sumatriptan-10-mg-with-a-permeation-enhancer-nasal-spray-vs-placebo-in-the-acute-treatment-of-migraine-a-double-blind-placebo-controlled-study
#14
Richard B Lipton, Sagar Munjal, Elimor Brand-Schieber, Alan M Rapoport
OBJECTIVE: The objective of this study was to evaluate the efficacy, safety, and tolerability of DFN-02 - a nasal spray comprising sumatriptan 10 mg and a permeation-enhancing excipient (0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside [DDM]) - for the acute treatment of migraine with or without aura in adults. BACKGROUND: Prior work has shown that DFN-02, which contains only half the recommended adult dose of sumatriptan found in the original formulation (10 mg vs 20 mg), is more rapidly absorbed than commercial nasal spray of sumatriptan, with favorable pharmacokinetic and safety profiles...
May 2018: Headache
https://www.readbyqxmd.com/read/29869205/cgrp-and-migraine-the-role-of-blocking-calcitonin-gene-related-peptide-ligand-and-receptor-in-the-management-of-migraine
#15
Kasra Maasumi, Rebecca L Michael, Alan M Rapoport
Migraine is a highly prevalent, complex neurological disorder. The burden of disease and the direct/indirect annual costs are enormous. Thus far, treatment options have been inadequate and mostly based on trial and error, leaving a significant unmet need for effective therapies. While the underlying pathophysiology of migraine is incompletely understood, blocking the calcitonin gene-related peptide (CGRP) using monoclonal antibodies targeting CGRP or its receptor and small molecule CGRP receptor antagonists (gepants) have emerged as a promising therapeutic opportunity for the management of migraine...
June 2018: Drugs
https://www.readbyqxmd.com/read/29868895/user-design-and-experience-preferences-in-a-novel-smartphone-application-for-migraine-management-a-think-aloud-study-of-the-relaxahead-application
#16
Mia T Minen, Adama Jalloh, Emma Ortega, Scott W Powers, Mary Ann Sevick, Richard B Lipton
Objective: Scalable nonpharmacologic treatment options are needed for chronic pain conditions. Migraine is an ideal condition to test smartphone-based mind-body interventions (MBIs) because it is a very prevalent, costly, disabling condition. Progressive muscle relaxation (PMR) is a standardized, evidence-based MBI previously adapted for smartphone applications for other conditions. We sought to examine the usability of the RELAXaHEAD application (app), which has a headache diary and PMR capability...
May 30, 2018: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/29862074/sphenopalatine-ganglion-block-for-the-treatment-of-acute-migraine-headache
#17
Mohamed Binfalah, Eman Alghawi, Eslam Shosha, Ali Alhilly, Moiz Bakhiet
Transnasal sphenopalatine ganglion block is emerging as is an attractive and effective treatment modality for acute migraine headaches, cluster headache, trigeminal neuralgia, and several other conditions. We assessed the efficacy and safety of this treatment using the Sphenocath® device. 55 patients with acute migraine headaches underwent this procedure, receiving 2 ml of 2% lidocaine in each nostril. Pain numeric rating scale (baseline, 15 minutes, 2 hours, and 24 hours) and patient global impression of change (2 hours and 24 hours after treatment) were recorded...
2018: Pain Research and Treatment
https://www.readbyqxmd.com/read/29848391/the-long-and-winding-road-the-journey-taken-by-headache-sufferers-in-search-of-help
#18
Paul T G Davies, Russell J M Lane, Theresa Astbury, Manuela Fontebasso, Jill Murphy, Manjit Matharu
AimTo outline the pathways a cohort of first attendees to our headache clinics had taken over the years in search of explanations and treatment for their headaches. To establish a greater awareness of the shortcomings and failures in their medical journey in the hope that better headache management will emerge in primary care. BACKGROUND: At first attendance in primary care most headache sufferers will not receive a firm diagnosis. Treatments provided are often ineffective and so many patients embark on a somewhat random self-made journey searching for a remedy...
May 31, 2018: Primary Health Care Research & Development
https://www.readbyqxmd.com/read/29848108/efficacy-and-safety-of-galcanezumab-for-the-prevention-of-episodic-migraine-results-of-the-evolve-2-phase-3-randomized-controlled-clinical-trial
#19
Vladimir Skljarevski, Manjit Matharu, Brian A Millen, Michael H Ossipov, Byung-Kun Kim, Jyun Yan Yang
Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention. Methods A global, double-blind, 6-month study of patients with episodic migraine was undertaken with 915 intent-to-treat patients randomized to monthly galcanezumab 120 mg (n = 231) or 240 mg (n = 223) or placebo (n = 461) subcutaneous injections. Primary endpoint was overall mean change from baseline in monthly migraine headache days. Key secondary endpoints were ≥50%,  ≥ 75%, and 100% response rates; monthly migraine headache days with acute migraine medication use; Patient Global Impression of Severity rating; the Role Function-Restrictive score of the Migraine-Specific Quality of Life Questionnaire...
July 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29813147/evaluation-of-galcanezumab-for-the-prevention-of-episodic-migraine-the-evolve-1-randomized-clinical-trial
#20
Virginia L Stauffer, David W Dodick, Qi Zhang, Jeffrey N Carter, Jessica Ailani, Robert R Conley
Importance: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. Objective: To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. Design, Setting, and Participants: The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic Migraine 1) trial was a double-blind, randomized, placebo-controlled (January 11, 2016, to March 22, 2017) trial comparing galcanezumab (120 mg and 240 mg) vs placebo...
May 29, 2018: JAMA Neurology
keyword
keyword
169485
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"